Home Tags BCMA-targeted therapies

Tag: BCMA-targeted therapies

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate or...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, and GlaxoSmothKline have entered into...